1. Clinical Overview
Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) designed for intraocular use. It binds to and inhibits the biological activity of all active forms of human vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis and vascular permeability. The 2.3mg/0.23mL formulation is a higher-dose option approved for specific retinal vascular conditions, offering a potential for extended durability of effect compared to the standard 0.5mg dose.
| Onset | Duration | Bioavailability |
|---|---|---|
| Pharmacodynamic effects (reduction in retinal thickness) can be observed within 24-48 hours. Clinical improvement in visual acuity typically begins within 1-4 weeks. | Variable; the therapeutic effect on VEGF suppression and disease activity typically lasts 4 to 8 weeks, necessitating repeat intravitreal injections. The 2.3mg dose may offer a longer treatment interval in some patients compared to 0.5mg. | 100% intraocular bioavailability following intravitreal injection. Systemic bioavailability is negligible (<1%). |
2. Mechanism of Action
Ranibizumab is a VEGF-A antagonist. It binds with high affinity to all biologically active isoforms of VEGF-A (e.g., VEGF110, VEGF121, VEGF165), preventing their interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This inhibition blocks key downstream signaling pathways that lead to endothelial cell proliferation, angiogenesis (new blood vessel formation), and increased vascular permeability.
3. Indications & Uses
- Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR) in patients with DME
4. Dosage & Administration
Adult Dosage: 2.3 mg (0.23 mL of the 10 mg/mL solution) administered by intravitreal injection once a month (approximately every 28 days). After the first 3-4 injections, treatment intervals may be extended based on disease activity as assessed by visual acuity and anatomical parameters (treat-and-extend or pro re nata [PRN] regimens).
Administration: FOR INTRAVITREAL USE ONLY. Administer under strict aseptic technique, including use of sterile gloves, drape, and eyelid speculum. Adequate anesthesia (topical or subconjunctival) and a broad-spectrum topical antimicrobial agent are required pre-injection. The injection is given 3.5-4.0 mm posterior to the limbus (in phakic patients) with a 30-gauge needle. Intraocular pressure and perfusion of the optic nerve head must be monitored post-injection.
5. Side Effects
Common side effects may include:
- Conjunctival hemorrhage
- Eye pain
- Vitreous floaters
- Increased intraocular pressure (transient)
- Foreign body sensation
- Lacrimation increased
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Anti-VEGF Agents (e.g., Aflibercept, Bevacizumab) | Theoretical risk of additive systemic VEGF suppression. Concurrent use in the same eye is not recommended. | Major |
| Anticoagulants/Antiplatelets (e.g., Warfarin, Clopidogrel, Aspirin) | May increase risk of intraocular or conjunctival hemorrhage during injection. Therapy is usually not discontinued but the risk is discussed. | Moderate |
| Antihypertensives | No direct interaction. However, controlling systemic hypertension is crucial in managing retinal vascular diseases. | Minor |
7. Patient Counselling
- Do report any new eye pain, redness, sensitivity to light, vision changes, or increase in floaters immediately.
- Do keep your scheduled follow-up appointments for monitoring and possible repeat injections.
- Do use prescribed topical antibiotic drops before and after the procedure as instructed.
- Don't rub or put pressure on the injected eye.
- Don't miss signs of systemic allergic reactions (rash, itching, dizziness) though rare.
8. Toxicology & Storage
Overdose: Intraocular overdose is theoretically possible. Symptoms could include severe intraocular inflammation, markedly increased intraocular pressure, and retinal toxicity. Systemic overdose is improbable due to the route of administration.
Storage: Store in a refrigerator at 2°C to 8°C. DO NOT FREEZE. Keep the pre-filled syringe in the outer carton to protect from light. The product should be allowed to reach room temperature naturally before use (approx. 30 minutes). Do not shake. Once the vial/syringe is opened, use immediately. It is for single use in one eye only. Discard any unused portion.